000			03926nam a22003735i 4500
999			_c80494 _d80494 _x1
001			80494
003			ES-MaUEC
005			20230207040307.0
007			cr nn 008mamaa
008			131212s2014 gw | s |||| 0|eng d
020			_a9783642384042
024	7		_a10.1007/978-3-642-38404-2 _2doi
040			_dES-MaUEC
050		4	_aRC270.8 _bE654 2014
245	1	0	_aEpigenetic Therapy of Cancer : _bPreclinical Models and Treatment Approaches _cedited by Michael Lübbert, Peter A. Jones
260			_aBerlin, Heidelberg _bSpringer _c2014
300			_a1 recurso en línea (X, 325 páginas) _b48 ilustraciones, 14 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aThe fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation -- Mouse models to study DNA methylation in cancer research -- Epigenetic regulation of normal hematopoietic development -- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies -- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches -- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins -- Epigenetic abnormalities in lung cancer -- Pharmacodynamic Responses to DNA Methyltransferase Inhibition -- Histone Methyltransferases: Opportunities in Cancer Drug Discovery -- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy -- Clinical Implications of Epigenetic Alterations in Lung Cancer -- Epigenetic disturbances in colorectal cancer -- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results.
520	3		_aThe growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors. This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
650		7	_aTerapia genética _2embne _9150702
650	2	7	_aTerapia genética _2embne _9150702
700	1		_aLübbert, Michael _eeditor literario _988732 _0Local
700	1		_aJones, Peter A. _eeditor literario _929627 _0comprobar BNE19999483644
710	2		_aSpringerLink (Online service) _0Local _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-642-38404-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12882471 _b10-10-17 _c11-11-15
942			_2lcc _cLE
945			_aRC270.8 E654 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11562298 _z06-04-17
988			_aEBOOK, asignarmaterias, EBSPRINGER,
998			_am _a_alco _a_vill _b11-11-15 _cm _dz _e- _feng _ggw _h0